Solventum Corporation
NYSE:SOLVMedical - Care Facilities
-$2.00 today
- Market cap
- $14.70B
- Beta
- 0.75
- P/E (TTM)
- 9.1
- EPS (TTM)
- $8.22
Volume 0.76M
Average 1.70M
SOLV Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Solventum CorporationNYSE: SOLV
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $133M rose 9.0% year over year, ahead of the -5.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.5% from the prior quarter. Over 3 fiscal years it compounded at -5.4% a year.
Context
- Depreciation & amortization amounted to 5.9% of revenue in FY2025, down 0.9 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +9.0% holds above the trailing-twelve-month pace of -5.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 489M USD
- Year-over-year change
- -11.9%
- 4-year CAGR
- -4.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 489M | -11.9% |
| FY2024 | 2024-12-31 | 555M | -1.1% |
| FY2023 | 2023-12-31 | 561M | -2.9% |
| FY2022 | 2022-12-31 | 578M | -3.2% |
| FY2021 | 2021-12-31 | 597M | — |
Depreciation & Amortization vs competitors
How SOLV compares with its peers on the latest reported figures
- SOLV's LTM Jun 2026 depreciation & amortization of $506M is the 3rd largest of the 10 companies compared; the peer median is $327M.
- Its year-over-year change of -5.2% is the 8th highest of 10, against a peer median of -1.5%.
- Depreciation & amortization amounts to 6.1% of revenue for SOLV, versus a peer median of 8.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.24B | -4.2% | -0.7% | 11.1% | |
| LTM Jun 2026 | $953M | -5.0% | -2.9% | 8.3% | |
| LTM Jun 2026 | $506M | -5.2% | -5.4% | 6.1% | |
| LTM Jul 2026 | $384M | +3.8% | +6.9% | 9.1% | |
| LTM Mar 2026 | $353M | +3.2% | +2.4% | 9.6% | |
| LTM Jun 2026 | $327M | +9.4% | +13.6% | 2.4% | |
| LTM Jun 2026 | $204.78M | -1.5% | -5.1% | 9.5% | |
| LTM Sep 2026 | $136.48M | +3.5% | +13.5% | 8.5% | |
| LTM Oct 2026 | $60.3M | -51.0% | -10.6% | 2.1% | |
| LTM Mar 2026 | $2.22M | -23.2% | -24.8% | 5.9% | |
| Peer median (excluding SOLV) | $327M | -1.5% | -0.7% | 8.5% | |
Competitors are the stored peer set for SOLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.46B | 1.34B | 1.35B | 479M | 1.56B |
| Depreciation & Amortization | 597M | 578M | 561M | 555M | 489M |
| Deferred Income Tax | (34M) | (141M) | (142M) | (155M) | (120M) |
| Stock-Based Compensation | 38M | 37M | 39M | 112M | 161M |
| Change in Working Capital | 67M | (202M) | 126M | 160M | (119M) |
| Accounts Receivables | (1M) | (32M) | (129M) | 276M | 78M |
| Inventory | (136M) | (82M) | 23M | (132M) | (139M) |
| Accounts Payables | 68M | 25M | 105M | 266M | 104M |
| Other Working Capital | 136M | (113M) | 127M | (250M) | (162M) |
| Other Non-Cash Items | 74M | 64M | (15M) | 34M | (1.6B) |
| Operating Cash Flow | 2.2B | 1.68B | 1.92B | 1.19B | 369M |
| Capital Expenditures | (277M) | (251M) | (290M) | (380M) | (379M) |
| Acquisitions (Net) | 0 | 0 | 60M | 0 | (696M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (1M) | (2M) | 0 | 0 | 3.87B |
| Investing Cash Flow | (278M) | (253M) | (230M) | (380M) | 2.8B |
| Debt Repayment | 0 | 0 | 0 | 8B | (3.07B) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.96B) | (1.46B) | (1.55B) | (8.24B) | 13M |
| Financing Cash Flow | (1.96B) | (1.46B) | (1.55B) | (240M) | (3.06B) |
| Effect of Forex Changes | 3M | 4M | 0 | 3M | 7M |
| Net Change in Cash | (33M) | (30M) | 133M | 568M | 116M |
| Free Cash Flow | 1.93B | 1.43B | 1.63B | 805M | (10M) |
Solventum Corporation
NYSE:SOLV
Intrinsic Alpha fair value
Locked
Current Price
$86.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.